ArticleBiology direct2026
Impeding hypoxia-driven tumor progression in hepatocellular carcinoma: clinical and pre-clinical analyses using 2D and 3D in vitro models.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHypoxia is a hallmark of the hepatocellular carcinoma (HCC) microenvironment, promoting tumor progression, therapy resistance, and poor prognosis. Central mediators of the hypoxic response are the hypoxia-inducible factors (HIFs), particularly HIF-1α, whose functional relevance in clinically representative models remains incompletely understood.
methodsIn this study, we performed an in-depth characterization and functional analysis of HIF-1α by generating HIF1A knockout (KO) models in two-dimensional (2D) and three-dimensional (3D) HCC culture systems, including tumor spheroids and fibrotic-like collagen-fibrin hydrogels, to better recapitulate the complexity of the tumor microenvironment (TME).
resultsAnalyses of publicly available transcriptomic datasets revealed that HIF1A was significantly upregulated in tumor tissues and associated with higher grade, stage, and poor survival. In contrast, EPAS1 was downregulated and correlated with improved outcomes. Functional silencing and KO experiments confirmed that HIF-1α promoted tumor cell survival, invasion, and adaptation to hypoxia, while HIF-2α played only a limited role. HIF1A deletion impaired the expression of downstream targets such as VEGF and BNIP3 and altered ABCB1 levels. Importantly, HIF-1α loss markedly reduced viability and structural integrity in 3D cultures, highlighting the added value of using physiologically relevant models to uncover microenvironment-driven phenotypes.
conclusionsAltogether, our results identify HIF-1α as a central regulator of hypoxia-mediated tumor behavior in HCC and provide a strong rationale for its therapeutic targeting to disrupt tumor adaptation and improve patient outcomes. Moreover, these findings underscore the relevance of integrating both advanced 3D and complex 2D culture systems to better capture the structural, biochemical, and mechanical features of the TME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.